In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis

In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis

Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.

Inclusion Criteria:

• Patients with active ulcerative colitis will receive infliximab antibody therapy.

Exclusion Criteria:

• Patients with impaired blood clotting.
• Patients with short bowel syndrome.
• Patients during the pregnancy and lactation period.
• Patients received enema therapy within 1 month before inclusion in the study, or had anti-TNF therapy within the last 12 months.
• Patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit.
• Patients with moderate to severe heart failure, active tuberculosis or acute infections.